TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05007184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chilean Warning Labels
Description: These labels were implemented in Chile in 2016. They are shown on those less-healthy food and beverage products that do not fall within thresholds that are defined for the following nutrients: sugar, sodium, calories and saturated fats. The original labels are in Spanish but the ones that we displayed were in Arabic.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutri-Score Labels
Description: These labels were implemented by the French government in 2017. They are shown on all food and beverage products and range from A to E with the corresponding colours moving from Green to Red (symbolizing best to worst). The scores and grades are calculated based on 7 different nutrients grouped into 2 categories i.e. nutrients to consume (such as fibre) and nutrients to avoid (such as sugar). We modified the labels by adding % sugar per serving on the right side of the labels.
Study: NCT05992428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8010 5mg
Description: \[Part 1\] DA-8010 5mg + Paroxetine 20mg \[Part 2\] DA-8010 5mg + Mirabegron 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine 20mg
Description: \[Part 1\] DA-8010 5mg + Paroxetine 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron 50mg
Description: \[Part 2\] DA-8010 5mg + Mirabegron 50mg
Study: NCT06400108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dementia Moves
Description: Dementia Moves: Dementia Moves is a multicomponent exercise program that can be individually tailored to the abilities of LTC residents with more advanced dementia and focuses on moderate- to high-intensity strength and balance activities with an aim to improve ADLs. Individualized strategies are implemented throughout the intervention to support and promote participation of individuals with more advanced dementia.~Each exercise will be individually prescribed for each participant by the physiotherapists (PT) at the beginning of the program. The intensity of the exercise will be adjusted throughout the program by the PT to ensure the target intensity of moderate to high intensity balance and strength exercises. The intervention will be provided face to face in groups of 4 residents with the PT, PTA, and three volunteers. Though the intervention is delivered in a group setting, the specific exercises that the participants complete are individualized based on their abilities.
Study: NCT06106451

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care plus Enhanced Patient Education
Description: Patients in this arm will receive a pamphlet explaining the benefits of cardiac rehabilitation. This pamphlet will be given in addition to standard of care patient education. The research team will also call the patient at four specified time points to provide additional information.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing Intervention
Description: Patients in this arm of the study will participate in a tailor-made motivational interviewing program. These motivational interviewing sessions will focus on enhancing communication with patients. Each motivational interviewing session will be approximately one hour long. There will be a total of 4-6 motivational interviewing sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based Activity Program plus Motivational Interviewing Intervention
Description: Patients in this arm will be evaluated on postoperative day 1 by a physical therapist on the study team. After the evaluation, the physical therapist will use the information from the evaluation to make a tailored home-based physical activity program for the patient. The patient will begin the home-based physical activity program on the day of their 1-month post-operative cardiology clinic appointment. In addition to the home-based activity program, patients will participate in a tailor-made motivational interviewing program. These motivational interviewing sessions will focus on enhancing communication with patients. Each motivational interviewing session will be approximately one hour long. There will be a total of 4-6 motivational interviewing sessions.
Study: NCT05295654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinect validation
Description: Participants will perform several movements while both the vicon and kinect are measuring.
Study: NCT05768659

Intervention type: BEHAVIORAL
Intervention: Fear Conditioning
Description: It is a 2-day paradigm. Participants will undergo an auditory fear conditioning task in 3 phases: (1) pre-conditioning habituation, (2) unconditioned stimulus (US) calibration, where USs will be delivered to set the individual stimulation intensity threshold, and (3) fear conditioning, in which participants will be exposed to the conditioned stimulus (CS) associated with the US with an 80% pairing rate. 24 hours later, the (1) implicit recognition of the CS and novel stimuli (NSs), and the (2) explicit recognition, through an alternative forced-choice task will be assessed. Also, (3) the perceptual discrimination (among the CS and NSs) will be tested.~Event-related skin conductance responses (SCRs) will be collected as an implicit index of defensive fear responses, while the accuracy in detecting and discriminating the CS from NSs as the explicit index. Psychological questionnaires about anxiety symptoms will be also administered.

Intervention type: BEHAVIORAL
Intervention: Fear Conditioning
Description: It is a 2-day paradigm. Participants will undergo an auditory fear conditioning task in 3 phases: (1) pre-conditioning habituation, (2) unconditioned stimulus (US) calibration, where USs will be delivered to set the individual stimulation intensity threshold, and (3) fear conditioning, in which participants will be exposed to the conditioned stimulus (CS) associated with the US with an 80% pairing rate. 24 hours later, the (1) implicit recognition of the CS and novel stimuli (NSs), and the (2) explicit recognition, through an alternative forced-choice task will be assessed. Also, (3) the perceptual discrimination (among the CS and NSs) will be tested.~Event-related skin conductance responses (SCRs) will be collected as an implicit index of defensive fear responses, while the accuracy in detecting and discriminating the CS from NSs as the explicit index. Psychological questionnaires about anxiety symptoms will be also administered.
Study: NCT05909566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS)
Description: Education to front line clinicians and staff on standardized implementation and weaning of HHFNC and standardized assessments of patient work of breathing. HHFNC implementation and weaning strategies will be based on age-specific practices recommended by the American Academy of Pediatrics. Education will be undertaken by dedicated clinical educators.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Decision Support (CDS)
Description: Education to front line clinicians and staff on standardized implementation and weaning of HHFNC and standardized assessments of patient work of breathing. HHFNC implementation and weaning strategies will be based on age-specific practices recommended by the American Academy of Pediatrics. Education will be undertaken by dedicated clinical educators.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HHFNC Weaning
Description: Wean patient off oxygen and flow as oxygenation and work of breathing improves.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HHFNC Weaning
Description: Wean patient off oxygen and flow as oxygenation and work of breathing improves.
Study: NCT05470933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WJ01075
Description: Phase Ia: Dose Escalation Accelerated titration (the first two dose groups) and 3 + 3 combination (the subsequent dose group) were used for dose escalation.~Phase Ib: Dose Expansion and Cohort Expansion The actual dose, dosing schedule (including combination) and indication selection will be evaluated based on the results of existing trials.
Study: NCT05924906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB002
Description: Strength: 100 mg:5 mL solution in a single-use vial Administration: intravenous infusion
Study: NCT05544864

Intervention type: DEVICE
Group type: OTHER
Intervention: Drug eluting stent (DES)
Description: DES-implantation with an everolimus-eluting stent (Xience, Abbott Vascular)

Intervention type: DEVICE
Group type: OTHER
Intervention: Drug eluting stent (DES)
Description: DES-implantation with an everolimus-eluting stent (Xience, Abbott Vascular)

Intervention type: DEVICE
Group type: OTHER
Intervention: Drug coated ballloon (DCB)
Description: DCB angioplasty with any commercially available drug-coated balloon
Study: NCT05924906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB002
Description: Strength: 100 mg:5 mL solution in a single-use vial Administration: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB002
Description: Strength: 100 mg:5 mL solution in a single-use vial Administration: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB002
Description: Strength: 100 mg:5 mL solution in a single-use vial Administration: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB002
Description: Strength: 100 mg:5 mL solution in a single-use vial Administration: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB002
Description: Strength: 100 mg:5 mL solution in a single-use vial Administration: intravenous infusion
Study: NCT05544864

Intervention type: DEVICE
Group type: OTHER
Intervention: Drug coated ballloon (DCB)
Description: DCB angioplasty with any commercially available drug-coated balloon
Study: NCT06207123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-118
Description: LP-118 is an experimental anti-cancer drug that is currently being studied in clinical trials for multiple types of hematological cancers and solid tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib is used to treat certain types of chronic myeloid leukemia (CML; a type of cancer of the white blood cells).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine is a chemotherapy medication used to treat various types of cancer, including leukemia, lymphoma, neuroblastoma, and Wilms tumor. Vincristine belongs to the category of vinca alkaloids, a class of drugs that function by impeding the proper division of cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone is used to treat cancer, to decrease inflammation and sometimes used before and after chemotherapy to prevent or treat nausea and/or vomiting. It is given in the vein (IV) or orally (by mouth)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate is a drug used to treat cancer of the blood, bone, lung, breast, head, and neck. It can also treat rheumatoid arthritis and psoriasis.
Study: NCT04780581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 6 mg/24h - 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 250 mg/ 24h - 3 days
Study: NCT04985799

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gynecare TVT Exact Continence System
Description: Participants will have placement of Gynecare TVT Exact sling.
Study: NCT05745623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-723
Description: ICP-723 tablet administered orally，once a day，for every 28 days as one cycle
Study: NCT05728502

Intervention type: DRUG
Intervention: Vericiguat (Verquvo, BAY1021189)
Description: Dosage at the discretion of the treating physician, based on the recommendations written in the product information.

Intervention type: DRUG
Intervention: Standard of Care (SoC)
Description: Dosage at the discretion of the treating physician.
Study: NCT04958265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crovalimab
Description: Crovalimab will be administered at a dose of 1000 mg intravenously (IV) (for participants weighing =\> 40 to \<100 kg) or 1500 mg IV (for participants weighing \>=100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg subcutaneously (SC). On Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants weighing =\> 40 to \<100 kg) or 1020 mg SC (for participants weighing \>=100 kg). Enrollment of participants weighing \<40 kg will be staggered using two weight-based dose confirmation groups (Group 1 participants weighing \>=20 kg to \<40 kg, followed by Group 2 participants weighing \>=5 kg to \<20 kg). All participants will receive an initial IV loading dose, which will be followed by SC dosing at either Q2W or Q4W intervals (depending on body weight), until study completion.
Study: NCT05852691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobemstomig
Description: Participants will receive intravenous (IV) tobemstomig every 3 weeks (Q3W) until disease progression or until up to 24 months after the first treatment, whichever is sooner.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Participants will receive IV pembrolizumab Q3W until disease progression or until up to 24 months after the first treatment, whichever is sooner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Participants will receive IV nab-paclitaxel weekly for 3 weeks, followed by 1 week off, until disease progression or until up to 24 months after the first treatment, whichever is sooner.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-Paclitaxel
Description: Participants will receive IV nab-paclitaxel weekly for 3 weeks, followed by 1 week off, until disease progression or until up to 24 months after the first treatment, whichever is sooner.
Study: NCT05679323

Intervention type: OTHER
Intervention: KATZ index of independence in activities of daily living
Description: KATZ index measures self-care tasks using a dichotomous rating (dependent-0/independent-1) including; bathing, dressing, toileting, transferring to and from a chair, maintaining continence, and feeding. Six points are considered independent and 0 points are considered fully dependent. Assessment of each patient is made through a phone call at day 1, 3 and 5 after discharge

Intervention type: OTHER
Intervention: KATZ index of independence in activities of daily living
Description: KATZ index measures self-care tasks using a dichotomous rating (dependent-0/independent-1) including; bathing, dressing, toileting, transferring to and from a chair, maintaining continence, and feeding. Six points are considered independent and 0 points are considered fully dependent. Assessment of each patient is made through a phone call at day 1, 3 and 5 after discharge
Study: NCT05654506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: 1800 mg subcutaneous (SC) injection (total amount 15 mL) into the right/left abdominal area once weekly for 8 doses followed by once every 2 weeks for an additional 8 doses
Study: NCT04985799

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neomedic KIM (Knotless Incontinence Mesh)
Description: Participants will have placement of retropubic Neomedic KIM (Knotless Incontinence Mesh) sling
Study: NCT06072482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacopan
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacopan
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: All participants will receive SoC background immunosuppressive therapy for induction and maintenance, at the discretion of the Investigator and as supported by current guidelines, product labels and local practices and informed by the individual participant's clinical condition, preferences, and values.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: All participants will receive SoC background immunosuppressive therapy for induction and maintenance, at the discretion of the Investigator and as supported by current guidelines, product labels and local practices and informed by the individual participant's clinical condition, preferences, and values.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: All participants will receive SoC background immunosuppressive therapy for induction and maintenance, at the discretion of the Investigator and as supported by current guidelines, product labels and local practices and informed by the individual participant's clinical condition, preferences, and values.
Study: NCT06579677

Intervention type: OTHER
Intervention: Without any intervention
Description: No interventions will be performed.
Study: NCT05259943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin first
Description: Participants will receive 8 doses of 2mg psilocybin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin first
Description: Participants will receive 8 doses of 2mg psilocybin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo first
Description: Participants will receive 4 doses of placebo followed by 4 doses of 2mg psilocybin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo first
Description: Participants will receive 4 doses of placebo followed by 4 doses of 2mg psilocybin
Study: NCT05192863

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT06405022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Endurance Training
Description: Six week period with three weekly blocks with a 20 min brain endurance training program following a regular HIT session. Before the HIT session questionnaires are completed to measure the motivation for the HIT session and the current state of mood. In between the HIT session and the RCA session, questionnaires are completed to measure the experienced workload of the HIT session, the current state of mood, and the motivation for following the RCA session. Immediately after the RCA session, questionnaires are completed to measure the experienced workload of the RCA session and the current state of mood.
Study: NCT06483737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human albumin infusion at a modified dosage
Description: Participants receive intravenous infusion of human albumin at different dosages according to the serum albumin level.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human albumin infusion at a routine dosage
Description: Participants receive intravenous infusion of human albumin according to the current clinical practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: All participants will receive standard treatment of overt HE according to the current practice guideline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: All participants will receive standard treatment of overt HE according to the current practice guideline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: All participants will receive standard treatment of overt HE according to the current practice guideline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: All participants will receive standard treatment of overt HE according to the current practice guideline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ornithine Aspartate
Description: All participants will receive standard treatment of overt HE according to the current practice guideline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ornithine Aspartate
Description: All participants will receive standard treatment of overt HE according to the current practice guideline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branched-Chain Amino Acids
Description: All participants will receive standard treatment of overt HE according to the current practice guideline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Branched-Chain Amino Acids
Description: All participants will receive standard treatment of overt HE according to the current practice guideline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine
Description: All participants will receive standard treatment of overt HE according to the current practice guideline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arginine
Description: All participants will receive standard treatment of overt HE according to the current practice guideline.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: plasma exchange
Description: All participants will receive standard treatment of overt HE according to the current practice guideline.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: plasma exchange
Description: All participants will receive standard treatment of overt HE according to the current practice guideline.